|
|
| | Tolazoline hydrochloride Basic information |
| | Tolazoline hydrochloride Chemical Properties |
| Melting point | 172-176 °C | | storage temp. | Inert atmosphere,Room Temperature | | solubility | DMSO (Slightly, Heated), Methanol (Slightly) | | form | Crystalline Powder | | color | White to almost white | | Sensitive | Hygroscopic | | Merck | 14,9506 | | Stability: | Hygroscopic | | CAS DataBase Reference | 59-97-2(CAS DataBase Reference) | | EPA Substance Registry System | Tolazoline hydrochloride (59-97-2) |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 22 | | RIDADR | 2811 | | TSCA | Yes | | HS Code | 29332900 | | Toxicity | LD50 orl-rat: 1200 mg/kg NIIRDN 6,511,82 |
| | Tolazoline hydrochloride Usage And Synthesis |
| Chemical Properties | Pale Yellow Crystalline Solid | | Originator | Priscoline,Ciba,US,1948 | | Uses | Αn α-adrenergic antagonist. A peripheral vasodilator. | | Uses | a-adrenergic antagonist. A peripheral vasodilator | | Uses | adrenergic blocker | | Definition | ChEBI: Tolazoline hydrochloride is a member of benzenes. | | Manufacturing Process | The phenyl-acetiminoether hydrochloride of the formula
from 12 parts of benzylcyanide and ethanol and HCl is mixed with 8 parts of
ethylenediamine hydrate which has been diluted with little alcohol, whereby
the crystals go into solution. The whole is then heated on the water-bath until
the ammonia odor has disappeared, cooled, concentrated caustic potash
solution added, and the separated oil extracted with ether. The solution is
dried with potassium carbonate and potassium hydroxide. After evaporation a
pale oil is left which distills at 147°C under a pressure of 9 mm and which
solidifies in the condenser to a white crystalline mass. The yield amounts to
90% of the theory. The hydrochloride melts at 168° to 170°C. | | Brand name | Tolazoline is INN and
BAN. | | Therapeutic Function | Vasodilator | | Safety Profile | Poison by ingestion,
intravenous, and intraperitoneal routes.
Human systemic effects by intravenous
route: change in heart rate, sweating,
ulceration or bleeding from duodeum,
ulceration or bleeding from small intestine,
unspecified vascular effects. When heated to
decomposition it emits very toxic fumes of
NO, and HCl. | | Veterinary Drugs and Treatments | flipping of lips); piloerection;
clear lacrimal & nasal discharge; muscle fasciculations;
apprehensiveness
Uses/Indications
Tolazoline is approved and indicated for the reversal of effects associated
with xylazine in horses. It has also been used for this purpose
in a variety of other species as well, but less safety and efficacy data
is available.
In humans, the primary uses for tolazoline are: treatment of persistent
pulmonary hypertension in newborns, adjunctive treatment
and diagnosis |
| | Tolazoline hydrochloride Preparation Products And Raw materials |
|